


CORRECTION

Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study

Loreta A. Kondili, Giovanni Battista Gaeta, Donatella Ieluzzi, Anna Linda Zignego, Monica Monti, Andrea Gori, Alessandro Soria, Giovanni Raimondo, Roberto Filomia, Alfredo Di Leo, Andrea Iannone, Marco Massari, Romina Corsini, Roberto Gulminetti, Alberto Gatti Comini, Pierluigi Toniutto, Denis Dissegna, Francesco Paolo Russo, Alberto Zanetto, Maria Grazia Rumi, Giuseppina Brancaccio, Elena Danieli, Maurizia Rossana Brunetto, Liliana Elena Weimer, Maria Giovanna Quaranta, Stefano Vella, Massimo Puoti

The graph that appears as [Fig 2A](#) is incorrectly duplicated in [Fig 2B](#). Please see the corrected [Fig 2](#) here.



OPEN ACCESS

Citation: Kondili LA, Gaeta GB, Ieluzzi D, Zignego AL, Monti M, Gori A, et al. (2018) Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. PLoS ONE 13(1): e0190803. <https://doi.org/10.1371/journal.pone.0190803>

Published: January 2, 2018

Copyright: © 2018 Kondili et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Fig 2. Category of potential DDIs, by DAA regimen and severity of liver disease, among HCV-infected patients. Comedication used in patients with mild liver disease (A) or in (B) patients with moderate-to severe-liver disease (B). DAA regimens and number of comedications used are shown. SOF/RBV: sofosbuvir plus ribavirin, SOF/SIM: sofosbuvir plus simeprevir, SOF/DCV: sofosbuvir plus daclatasvir, SOF/LDV: sofosbuvir plus ledipasvir, 3D: paritaprevir/ritonavir, ombitasvir, dasabuvir. Category 0: Classification not possible due to lack of information; Category 1: No clinical interaction possible; Category 2: May require dose adjustment/closer monitoring.

<https://doi.org/10.1371/journal.pone.0190803.g001>

Reference

1. Kondili LA, Gaeta GB, Ieluzzi D, Zignego AL, Monti M, Gori A, et al. (2017) Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. *PLoS ONE* 12(2): e0172159. <https://doi.org/10.1371/journal.pone.0172159> PMID: 28245248